- Home
- PETZ vs HSCS Comparison
PETZ vs HSCS Comparison
Compare PETZ & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- HSCS
- Stock Information
- Founded
- PETZ 2002
- HSCS 2007
- Country
- PETZ China
- HSCS United States
- Employees
- PETZ N/A
- HSCS N/A
- Industry
- PETZ Steel/Iron Ore
- HSCS Medical Specialities
- Sector
- PETZ Industrials
- HSCS Health Care
- Exchange
- PETZ Nasdaq
- HSCS Nasdaq
- Market Cap
- PETZ 9.3M
- HSCS 9.9M
- IPO Year
- PETZ 2017
- HSCS 2022
- Fundamental
- Price
- PETZ $1.09
- HSCS $3.64
- Analyst Decision
- PETZ
- HSCS Strong Buy
- Analyst Count
- PETZ 0
- HSCS 2
- Target Price
- PETZ N/A
- HSCS $10.50
- AVG Volume (30 Days)
- PETZ 246.3K
- HSCS 93.8K
- Earning Date
- PETZ 04-28-2025
- HSCS 09-11-2025
- Dividend Yield
- PETZ N/A
- HSCS N/A
- EPS Growth
- PETZ N/A
- HSCS N/A
- EPS
- PETZ 0.26
- HSCS N/A
- Revenue
- PETZ $563,726.00
- HSCS $6,250.00
- Revenue This Year
- PETZ N/A
- HSCS $13,968.97
- Revenue Next Year
- PETZ N/A
- HSCS $166.67
- P/E Ratio
- PETZ $5.51
- HSCS N/A
- Revenue Growth
- PETZ 74664.72
- HSCS N/A
- 52 Week Low
- PETZ $0.65
- HSCS $2.52
- 52 Week High
- PETZ $1.74
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- PETZ 49.23
- HSCS 53.69
- Support Level
- PETZ $1.06
- HSCS $3.29
- Resistance Level
- PETZ $1.19
- HSCS $3.80
- Average True Range (ATR)
- PETZ 0.06
- HSCS 0.18
- MACD
- PETZ -0.00
- HSCS 0.02
- Stochastic Oscillator
- PETZ 23.33
- HSCS 68.63
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.